New research reveals semaglutide, the active ingredient in Wegovy, shows promise in treating metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease affecting millions. The study indicates significant improvements in liver health among participants, leading to hopes for FDA approval.
Novo Nordisk is partnering with telehealth providers Hims & Hers, Ro, and Life MD to make its weight loss drug Wegovy more accessible. Shares soar as Wegovy becomes readily available.
Hims & Hers Health shares skyrocketed nearly 30% in premarket trading following a groundbreaking partnership with Novo Nordisk to sell the weight loss drug Wegovy. Discover what this means for investors!
